For your adult patients with relapsed
or refractory multiple myeloma

UNPRECEDENTED
mPFS:
~42 MONTHS
WITH SARCLISA + Kd1-5

Longest ever reported

in a phase 3 trial that included lenalidomide-refractory patients*

*Based on a review of published phase 3 trials that included lenalidomide-refractory patients with RRMM. Interpret with caution, as various factors, including patient population, differ between trials.

IKEMA mPFS: 41.7 months with SARCLISA + Kd (n=179) vs 20.8 months with Kd alone (n=123), HR=0.59 (95% CI: 0.42, 0.83) at a median follow-up of 44 months

Superior PFS vs Kd at
interim analysis

(median follow-up of 20.7 months)1

SARCLISA + Kd: mPFS NR
Kd: mPFS 20.27 months1

HR=0.548
(95% CI: 0.37, 0.82; P=0.0032)1

See the final mPFS analysis from the IKEMA trial

Explore sarclisa + Kd

Consider sarclisa + Kd
at
first relapse1

Explore Patient Types

See the anti-CD38 monoclonal
antibody of SARCLISA1

Explore the MOA

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
for Multiple Myeloma recommend isatuximab-irfc (sarclisa) as a Category 1 Preferred option for early relapses6†

  • In combination with pomalidomide and dexamethasone‡
  • In combination with carfilzomib and dexamethasone

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

†1-3 prior therapies.6 Recommendation for isatuximab-irfc (SARCLISA) in combination with carfilzomib and dexamethasone based on results of interim analysis.
‡After 2 prior therapies including lenalidomide and a proteasome inhibitor.6

Kd=carfilzomib and dexamethasone; MOA=mechanism of action; mPFS=median progression-free survival; NCCN=National Comprehensive Cancer Network (NCCN®); NR=not reached; PFS=progression-free survival; RRMM=relapsed or refractory multiple myeloma.

References: 1. SARCLISA [prescribing information]. Bridgewater, NJ: sanofi-aventis U.S. LLC. 2. Moreau P, Dimopoulos M-A, Mikhael J, et al; IKEMA study group. Updated progression-free survival and depth of response in IKEMA, a randomized phase 3 trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma. Presented at: the 8th World Congress on Controversies in Multiple Myeloma (COMy); May 12-15, 2022; Paris, France. 3. Hernández-Rivas J-A, Ríos-Tamayo R, Encinas C, Lahuerta J-J. The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies. Biomarker Res. 2022;10(1):1-23. 4. Usmani SZ, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol. 2022;23:65-76. 5. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25(25):3892-3901. 6. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma V.1.2023. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed October 24, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org.
Back to topTop